pharma’s Almanac: How is an increased focus on patient-centric concerns influencing the way that you work? July 21, 2023
OncLive: Dr. Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC June 26, 2023
Target Cancer Podcast: Train our immune system to kill cancer and prevent recurrence November 14, 2022
Pharma’s Almanac Roundtable: What is your plan to build a more sustainable business practice in the coming years? October 11, 2022
CancerNetwork: Nicholas Coupe, MBBS, PhD, Provides Update on Phase 2 Study of IMM60 in Advanced Melanoma/NSCLC August 4, 2022
ENDPOINTS: Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline July 20, 2022
ENDPOINTS: Low-profile biotech led by Bristol Myers vets grabs a suite of adenosine receptor antagonists via tiny buyout July 7, 2022
PharmaShots: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs June 8, 2022
BioSpace: AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology April 15, 2022
PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021 September 13, 2021
Business of Biotech: iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters August 30, 2021
Empowered Patient Podcast: Stimulating Invariant Natural Killer T-Cells to Boost Immune System in Fight Against Cancer May 25, 2021
Juvenescence CEO reveals why its deal with Portage is the smart choice for its longevity IP portfolio March 9, 2021
CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector December 1, 2020
